期刊
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
卷 176, 期 -, 页码 21-31出版社
ELSEVIER
DOI: 10.1016/j.ejpb.2022.05.006
关键词
Non-small cell lung cancer; Atezolizumab; Technetium-99m; Radiopharmaceutical; Nanoparticles; Biodistribution
资金
- Scientific and Technological Research Council of Turkey [TUBITAK-220/S/361]
- T.R. Prime Ministry State Planning Organization Foun-dation Grant [09DPT001]
A new type of nanoparticles was developed for precise imaging of lung cancer tumors, demonstrating high cytotoxic effects on tumor cells. These nanoparticles significantly improved the biodistribution at the tumor site.
Lung cancer (LC) is a common type of cancer, which is a leading cause of death around the world. There is an urgency for the development of new drugs that could diagnose the LC in the early stages and in a precise manner. In this direction, the development of nanoparticles radiolabeled with the diagnostic radioisotopes represent an important advance in the field of cancer imaging. In this study were developed PLA/PVA/Atezolizumab nano particles which were radiolabeled with 99mTc (Technetium-99m). The radiolabeled nanoparticles were evaluated in both: in-vitro (L-929 and A-549) as in-vivo (mice). The results showed no cytotoxicity effect in the healthy cells (L-929) and cytotoxicity effect in the tumor cells (A-549). The biodistribution assay demonstrated that 99mTc-PLA/PVA/Atezolizumab could reach the tumor site 14-folds higher than the nonparticulate atezolizumab. In conclusion, 99mTc-PLA/PVA/Atezolizumab nanoparticles showed to be a new drug which is able to precisely image the lung tumor, and it must be considered for clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据